Abstract
Objective: To investigate the relationship between the extent of cutaneous involvement by psoriasis among patients in a tertiary outpatient clinic and impact felt on the quality of life. Methods: A descriptive, retrospective study with a quantitative approach. Data was obtained from a sample of 31 patients treated at HU-UFPI’s dermatology clinic in the time range from 2022 to 2025, in whose chart a PASI was recorded, who agreed to feed information about their quality of life at time of diagnosis to the PDI. Normality was assessed by the Shapiro-Wilk method, and correlation between indices was assessed by Spearmann’s correlation test. Results: A positive correlation between PASI and PDI was found (ρ = 0,27), however, it was statistically insignificant (p = 0,14), and data was widely dispersed. A few relevant differences were found between specific subgroups, with greater impact on daily life and work among the unemployed and women, regardless of clinical severity. Conclusion: Studies with a larger sample size are necessary to establish a strong relationship between PASI and PDI. The weakly positive correlation found, though statistically insignificant, reinforces the individuality of experiencing psoriasis, and the relevance of individualized treatment plans.
References
AALEMI AK, et al. Correlation of Psoriasis Disability Index and Psoriasis Area and Severity Index: a study from Afghanistan. Clinical, Cosmetic and Investigational Dermatology, 2022; 15: 559–566.
ALAMRI A, et al. Psoriasis in Saudi population: gender differences in QoL. Cureus, 2022; 14(3): 22892.
BARBETTA PA. Estatística aplicada às ciências sociais. Florianópolis: Editora UFSC, 2014; 7.
COATES LC, et al. Global patient-based survey assessing the impact of psoriatic arthritis. Health Qual Life Outcomes, 2020; 18(1): 173.
ELGAMAL EAE, et al. Quality of life in mothers of children with psoriasis. Journal of Cosmetic Dermatology, 2023; 22(9): 2560-2564.
FINLAY AY e KELLY SE. Psoriasis: an index of disability. Clinical and Experimental Dermatology, 1987; 12: 8-11.
FINLAY AY e KHAN GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 1994; 19(3): 210–216.
FREDE N, et al. Psoriasis and psoriatic arthritis have major impact on QoL. Rheumatology and Therapy, 2023; 10: 711-723.
FREDRIKSSON T e PETTERSSON U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica, 1978; 157: 238–244.
GHEZZI G, et al. Health-related quality of life in psoriasis: literature review. Journal of Clinical Medicine, 2024; 13(16): 4623.
GRIFFITHS CEM, et al. Psoriasis. The Lancet, 2021; 397(10281): 1301–1315.
JENSEN MB, et al. Sex differences in DLQI in psoriasis. Acta Dermato-Venereologica, 2024; 104: 42441.
KVIST-HANSEN A, et al. Psoriasis is a disease with several clinical presentations. Ugeskr Laeger, 2024; 186(46): 6240401.
MANCHANDA Y, et al. Disease assessment in psoriasis. Indian Journal of Dermatology, 2023; 68(3).
MARONESE CA, et al. Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options. Journal of Investigative Dermatology, 2024; 144(11): 2364-2376.
ROLLIN L, et al. Psoriasis érythrodermique. Revue du Praticien, 2024; 74(1): 56-57.
ROMITI R, et al. Brazilian Consensus on Psoriasis 2020 and Treatment Algorithm of the Brazilian Society of Dermatology. Anais Brasileiros de Dermatologia, 2021; 96(6): 778-781.
ROMITI R, et al. Highlights of the Brazilian Society of Dermatology's Brazilian Consensus on Psoriasis. Anais Brasileiros de Dermatologia, 2025; 100(6): 501242.
SHAPIRO SS e WILK MB. An analysis of variance test for normality (complete samples). Biometrika, 1965; 52(3–4): 591–611.
TASHIRO T e SAWADA Y. Psoriasis and Systemic Inflammatory Disorders. International Journal of Molecular Sciences, 2022; 23(8): 4457.
